BTIG Reports That They Have Downgraded NeoGenomics (NASDAQ:NEO) Shares

September 13, 2017 - By Darrin Black

 BTIG Reports That They Have Downgraded NeoGenomics (NASDAQ:NEO) Shares

Investors sentiment decreased to 1.15 in 2016 Q4. Its down 0.10, from 1.25 in 2016Q3. It dropped, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.

Northwestern Mutual Wealth Mngmt Communications holds 0% or 8,487 shares. Axiom International Investors Ltd De holds 285,725 shares or 0.07% of its portfolio. Howland Mgmt has 0.01% invested in NeoGenomics, Inc. (NASDAQ:NEO). Blackrock Investment Mngmt Lc has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). 25,000 are owned by South State Corp. Emerald Advisers Pa stated it has 977,256 shares or 0.36% of all its holdings. Barclays Public invested in 0% or 59,731 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 3,530 shares. Timpani Mgmt Lc has 0.72% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 202,133 shares. The Massachusetts-based Geode Mngmt Ltd Liability has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Falcon Point Limited Company reported 253,239 shares stake. Gamco Incorporated Et Al has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Deutsche Fincl Bank Ag holds 42,587 shares. Cambridge Invest Research Advisors reported 12,600 shares. Creative Planning accumulated 6,500 shares.

Since May 25, 2017, it had 0 insider buys, and 2 selling transactions for $574,394 activity. 70,833 shares were sold by ROSS STEVEN A, worth $549,389.

NeoGenomics (NASDAQ:NEO) Receives a Downgrade

In analysts report shared with investors on 11 September, BTIG revealed that they have decided to downgrade shares of NeoGenomics (NASDAQ:NEO) to a “Hold”.

Investors sentiment decreased to 1.15 in 2016 Q4. Its down 0.10, from 1.25 in 2016Q3. It dropped, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.

Northwestern Mutual Wealth Mngmt Communications holds 0% or 8,487 shares. Axiom International Investors Ltd De holds 285,725 shares or 0.07% of its portfolio. Howland Mgmt has 0.01% invested in NeoGenomics, Inc. (NASDAQ:NEO). Blackrock Investment Mngmt Lc has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). 25,000 are owned by South State Corp. Emerald Advisers Pa stated it has 977,256 shares or 0.36% of all its holdings. Barclays Public invested in 0% or 59,731 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 3,530 shares. Timpani Mgmt Lc has 0.72% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 202,133 shares. The Massachusetts-based Geode Mngmt Ltd Liability has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Falcon Point Limited Company reported 253,239 shares stake. Gamco Incorporated Et Al has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Deutsche Fincl Bank Ag holds 42,587 shares. Cambridge Invest Research Advisors reported 12,600 shares. Creative Planning accumulated 6,500 shares.

Since May 25, 2017, it had 0 insider buys, and 2 selling transactions for $574,394 activity. 70,833 shares were sold by ROSS STEVEN A, worth $549,389.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

Among 10 analysts covering NeoGenomics (NASDAQ:NEO), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. NeoGenomics has $11 highest and $8 lowest target. $10.07’s average target is -0.40% below currents $10.11 stock price. NeoGenomics had 16 analyst reports since September 3, 2015 according to SRatingsIntel. Roth Capital maintained the shares of NEO in report on Thursday, September 3 with “Buy” rating. The stock has “Buy” rating by TH Capital on Monday, October 26. As per Wednesday, May 11, the company rating was reinitiated by Roth Capital. The firm has “Outperform” rating given on Sunday, September 6 by William Blair. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Buy” rating by BTIG Research on Friday, May 26. Cantor Fitzgerald maintained NeoGenomics, Inc. (NASDAQ:NEO) rating on Friday, May 26. Cantor Fitzgerald has “Buy” rating and $1100 target. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Neutral” rating by BTIG Research on Monday, September 11. Benchmark initiated it with “Buy” rating and $8 target in Friday, March 11 report. The rating was downgraded by Axiom Capital on Wednesday, November 16 to “Sell”. The firm earned “Overweight” rating on Thursday, December 15 by Cantor Fitzgerald.

The stock increased 0.10% or $0.01 during the last trading session, reaching $10.11. About 292,937 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since September 13, 2016 and is downtrending. It has underperformed by 30.16% the S&P500.

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The company has market cap of $802.61 million. The Firm operates in Laboratory Testing Segment. It currently has negative earnings. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com